Interactions of abiraterone, eplerenone and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100

Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an anti-androgen. Abiraterone, a rationally-designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate can...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Richards, Juliet, Lim, Ai Chiin, Hay, Colin W, Taylor, Angela E., Wingate, Anna, Nowakowska, Karolina, Pezaro, Carmel, Carreira, Suzanne, Goodall, Jane, Arlt, Wiebke, McEwan, Iain J, de Bono, Johann S, Attard, Gerhardt
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4281708/
https://ncbi.nlm.nih.gov/pubmed/22411952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3980
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky